Molecular and Cellular Biology, June 2001, p. 4032-4045, Vol. 21, No. 12
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.12.4032-4045.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Department of Cell Biology, Vontz Center for
Molecular Studies, University of Cincinnati, College of Medicine,
Cincinnati, Ohio 45267-0521,1 and Dumont
Transplant Center, University of California
Los Angeles School of
Medicine, Los Angeles, California 90095-70542
Received 5 December 2000/Returned for modification 16 January 2001/Accepted 13 March 2001
| |
ABSTRACT |
|---|
|
|
|---|
The retinoblastoma tumor suppressor protein (RB) is a negative regulator of the cell cycle that inhibits both G1 and S-phase progression. While RB-mediated G1 inhibition has been extensively studied, the mechanism utilized for S-phase inhibition is unknown. To delineate the mechanism through which RB inhibits DNA replication, we generated cells which inducibly express a constitutively active allele of RB (PSM-RB). We show that RB-mediated S-phase inhibition does not inhibit the chromatin binding function of MCM2 or RPA, suggesting that RB does not regulate the prereplication complex or disrupt early initiation events. However, activation of RB in S-phase cells disrupts the chromatin tethering of PCNA, a requisite component of the DNA replication machinery. The action of RB was S phase specific and did not inhibit the DNA damage-mediated association of PCNA with chromatin. We also show that RB-mediated PCNA inhibition was dependent on downregulation of CDK2 activity, which was achieved through the downregulation of cyclin A. Importantly, restoration of cyclin-dependent kinase 2 (CDK2)-cyclin A and thus PCNA activity partially restored S-phase progression in the presence of active RB. Therefore, the data presented identify RB-mediated regulation of PCNA activity via CDK2 attenuation as a mechanism through which RB regulates S-phase progression. Together, these findings identify a novel pathway of RB-mediated replication inhibition.
| |
INTRODUCTION |
|---|
|
|
|---|
The retinoblastoma tumor suppressor protein RB is a critical negative regulator of cell cycle progression (1, 24, 54, 6 2, 63). Extensive analysis has shown that RB functions as a protein-binding protein, assembling multiprotein complexes that regulate gene transcription (24, 62, 63). For example, RB binds to the E2F transcription factor and recruits histone deacetylase through an independent protein-binding module to repress specific E2F target genes (4, 42). Similarly, RB interacts with Brg-1 to mediate transcriptional repression of discrete target genes (57, 65). Naturally occurring mutant alleles of RB found in tumors invariably disrupt RB-mediated transcriptional repression function, lending credence to the hypothesis that this function is required to block inappropriate proliferation.
Cell cycle progression is a highly ordered process driven by the activity of cyclin-dependent kinase (CDK)-cyclin complexes. Mitogenic signaling interfaces with the cell cycle machinery through the activation of D-type cyclins and their associated catalytic subunits (CDK4 or CDK6) (1, 52, 54). The CDK-cyclin D complexes initiate the phosphorylation of RB in mid-G1, with complete RB hyperphosphorylation mediated by CDK2-associated kinase activity (43). RB is the critical substrate for cyclin D-associated kinase activity, as cyclin D and CDK4 are not required in the absence of functional RB (38, 40). In contrast, CDK2-cyclin E and -cyclin A complexes have additional substrates, as RB-deficient cells are readily arrested by attenuation of CDK2 activity (46). CDK-mediated phosphorylation of RB disrupts its protein-binding activity, transcriptional repression activity, and growth-inhibitory function (5, 21, 27, 43, 62).
To study RB function, we previously generated mutants of RB that are resistant to CDK phosphorylation (PSM-RB), since wild-type RB is rapidly phosphorylated by endogenous CDK activity (26, 28). PSM-RB proteins are potent inhibitors of cell cycle progression (29). We and others have previously shown that tumor cells must bypass RB-mediated transcriptional repression to escape PSM-RB-mediated cell cycle arrest (9, 26, 32, 39, 57, 65). In general, RB-mediated cell cycle inhibition is dependent on the downregulation of transcriptional targets that stimulate CDK2 activity (26, 37, 41, 65).
It has recently been demonstrated that RB is also an important regulator of S-phase progression (9, 26, 41, 65). Initially, it was found that the introduction of PSM-RB alleles into S-phase cells inhibits DNA replication (9, 26). Subsequently, it has been shown that endogenous RB is required to inhibit cellular DNA replication in response to specific stresses (31, 53). For example, DNA damage promotes RB dephosphorylation and activation in S-phase cells. This dephosphorylation-activation of RB precedes the inhibition of DNA synthesis induced by genotoxic damage and is required for S-phase inhibition, as RB-deficient cells continue DNA replication in the presence of DNA damage that blocks replication in matched RB-positive cells (31). Similarly, the expression of adeno-associated virus replication protein 78 arrests DNA replication via the activation of endogenous RB (53). Together, these studies indicate that RB regulates both G1 and S-phase progression and is required for the appropriate response to specific environmental stresses. The mechanism underlying RB regulation of DNA synthesis has not been described.
DNA replication is regulated to ensure the accurate duplication of
genetic material only once per cell division cycle (12, 25, 56,
61). In early G1, multiprotein complexes containing ORC, MCM, and cdc6 proteins assemble at origins of replication (pre-replication complex [preRC]) (10, 11, 12, 18, 25, 56,
61). As cells enter S phase, discrete origins of replication fire, leading to the displacement of MCM and cdc6 from the origin (10, 11, 23, 25, 48, 58). Upon DNA unwinding, RPA and
additional factors bind to the single-stranded DNA (61). Subsequently, replication factor C (RFC) loads PCNA onto chromatin; PCNA in turn recruits DNA polymerase
and serves as a processivity factor during DNA synthesis (61). Discontinuous origin
activation and DNA polymerase-mediated elongation events continue until
all origins have been replicated and MCM proteins are no longer
associated with the chromatin (10, 11, 25, 56, 61).
Disruption of any of these discrete processes leads to the inhibition
of DNA replication.
Here we sought to identify the mechanism by which RB regulates DNA synthesis. Cells which harbor inducible expression of PSM-RB were generated. Using these cells, we show that active RB inhibits DNA replication in both S-phase-synchronized and asynchronously proliferating cells. We show that RB activation does not disrupt MCM2 or RPA chromatin tethering, suggesting that RB does not affect the establishment or maintenance of the preRC or early initiation events; however, induction of PSM-RB specifically disrupted PCNA activity. The ability of RB to regulate PCNA was dependent on the inhibition of CDK2 activity, as achieved through downregulation of cyclin A expression. Although the chromatin association of PCNA was dependent on CDK2 activity, we show that this regulation can be dissociated from the presence of cyclin A. Lastly, restoration of CDK2-cyclin A activity restored PCNA tethering and partially reversed PSM-RB-mediated inhibition of DNA replication. Together, these data demonstrate that RB inhibits DNA synthesis through CDK2-mediated regulation of PCNA tethering. These data are the first to delineate a pathway of RB action upon the DNA replication machinery.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Cloning, cell culture, and synchronization. PSM-RB (PSM.7-LP) was subcloned into the unique BamHI site of the expression pTRE plasmid (Clontech). This plasmid was cotransfected with the pTK-Hyg plasmid into Rat 16 cells. The Rat 16 cells were engineered to express the Tet-VP16 fusion protein and provide tight regulation of Tet-regulated gene expression. These cells were kindly provided by S. Salama and E. Harlow (Massachusetts General Hospital). Several clones expressing PSM-RB were isolated, and one (A2-4: PSM.7-LP) was used for the present study. Consistent S-phase inhibition is observed with independent clones and other PSM-RB alleles.
The cell lines harboring inducible expression of PSM-RB were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 1 µg of doxycycline (Dox) per ml to keep the expression of active RB off. Culture media also contained 10% fetal bovine serum (FBS), hygromycin B (200 µg/ml), and G418 (400 µg/ml). To induce PSM-RB expression, cells were washed three times in phosphate-buffered saline (PBS) and subsequently placed into media lacking Dox. In order to synchronize cells in quiescence, asynchronously growing cells were cultured in 0.1% FBS for 72 h in the presence of Dox. To induce PSM-RB expression in these cultures, cells were washed with PBS after 48 h in 0.1% FBS and then placed in medium containing 0.1% FBS in either the presence or absence of Dox for an additional 24 h. Following synchronization in quiescence, cells were serum stimulated by adding fresh medium containing 10% FBS either with or without Dox. To synchronize cells in early S phase, proliferating cells with Dox were first made quiescent with 0.1% FBS, placed into 10% FBS for 16 h, and then incubated in the presence of aphidicolin (APH; 2 µg/ml; Sigma) for 10 h. This concentration of aphidicolin does not prevent initiation but impedes chain elongation (6, 11, 36). Thus, PCNA is tethered to chromatin under these conditions (3, 7). To induce active RB expression in these S-phase cultures, the APH-synchronized cells were washed with PBS and placed in medium containing aphidicolin in either the presence (PSM-RB expression off) or absence (PSM-RB expression induced) of Dox. These matched APH-synchronized cell populations were used for reverse transcription (RT)-PCR analysis, analysis of replication proteins, and analysis of CDK-cyclin expression and activity. To monitor S-phase progression, APH-synchronized cells that were cultured either with or without Dox were released from the aphidicolin block by washing as previously described (26) and propagated in medium containing or lacking Dox, respectively.Reporter assays. Approximately 3 × 105 cells were plated in 60-mm dishes. Cells were transfected with 8 µg of total plasmid DNA using FuGENE 6 (Roche) according to the manufacturer's instructions. Sixteen hours posttransfection, APH was added to synchronize cells in S-phase. After sixteen hours, cells were switched to media with or without Dox but containing APH. Sixteen hours after PSM-RB induction, cells were harvested and processed for relative luciferase activity as described previously (32). The plasmids used have been previously described (32).
RT-PCR. Total cellular RNA was isolated with Trizol reagent (Gibco-BRL) according to the manufacturer's instructions. First-strand cDNAs were synthesized from 1 µg of RNA by use of ThermoScript RT-PCR system (Gibco-BRL) following the manufacturer's protocol. cDNAs were subjected to PCR amplifications using the PCR Core System I (Promega) with two sets of primers specific for glyceraldheyde-3-phosphate dehydrogenase (GAPDH) (5'-GGTCATCAATGGGAAACCCATCAC-3' and 3'-TGATGGCATGGACTGTGGTCATGA-5') and cyclin A (5'-AGACCCTGCATTTGGCTGTG-3' and 3'-ACAAACTCTGCTACTTCTGG-5'). PCR was performed with the following conditions: 94°C for 4 min, 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s for 26 cycles. Approximately 10 µl of the PCR products was then separated by electrophoresis on a 2% agarose gel. The PCR products were visualized by ethidium bromide staining and then photographed (26).
Immunofluorescence microscopy. Approximately 105 cells were seeded on glass coverslips in six-well dishes. For bromodeoxyuridine (BrdU) incorporation, cells were labeled with BrdU for the indicated period of time and stained for BrdU incorporation as previously described (30).
For PCNA, MCM2, RPA, and lamin B immunofluorescence, cells were grown on coverslips which were washed and incubated in cold PBS and fixed with methanol (unextracted) for 5 min at room temperature. For staining of chromatin-tethered proteins, coverslips were washed three times in cold PBS and extracted with a modification of cold CSK buffer (10 mM PIPES [piperazine N,N'-bis(2-ethanesulfonic acid), pH 6.8], 100 mM NaCl, 300 mM sucrose, 1 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride) supplemented with 0.1% Triton X-100 and protease inhibitors for 20 min at 4°C before fixing in methanol. The following primary antibodies were used: PCNA (PC10; Santa Cruz), lamin B (sc-6217; Santa Cruz), MCM2 (46), and RPA (Ab-3; Oncogene Research Products).Nuclear fractionation and immunoblotting. A modification of a previously described method by Fujita et al. (19) was used to isolate chromatin-bound proteins. Briefly, cells were cultured in 100-mm plates, washed three times with ice-cold PBS, collected in 1 ml of PBS by scraping, and pelleted by quick spinning at 1,000 rpm for 1 to 2 min. Soluble proteins were then extracted with ice-cold 0.1% Triton X-100 in CSK buffer for 20 min at 4°C. The insoluble, chromatin-bound fraction was then pelleted by low-speed centrifugation at 3,000 rpm for 5 min at 4°C. These pellets were then reextracted by incubating in CSK buffer and collected by centrifugation at 3,000 rpm for 10 min at 4°C. The final pellet fraction (containing chromatin-bound proteins) or total cell pellets were solubilized in radioimmunoprecipitation assay (RIPA) buffer and equal protein was resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). Immunoblotting and kinase assays were performed using standard procedures and the following antibodies: cyclin A (C-19 or H432; Santa Cruz), cyclin E (M20; Santa Cruz), and CDK2 (M2-G; Santa Cruz), and PSM-RB was detected using 851 antibody (64).
Flow cytometry analysis. Following cell synchronization and drug treatments, cells were harvested by trypsinization, fixed with ethanol, and processed for propidium iodide staining as described (26). For bivariate flow analyses, cells were pulse labeled with BrdU for 1 h and then processed for BrdU staining and propidium iodide staining (31).
Adenoviral infections. Cyclin A-green fluorescent protein (GFP) and GFP adenoviruses were a kind gift from Gustavo Leone (Ohio State University). Approximately 105 cells were seeded on coverslips in six-well dishes and synchronized in S-phase as described above. Just before infection, cells were washed with PBS and switched to media with and without Dox in the presence of APH. The infections were performed at a calculated multiplicity of infection (MOI) of 50 to 100 (the actual infection efficiency was approximately 95 to 100%, as determined by GFP fluorescence) for 16 h.
| |
RESULTS |
|---|
|
|
|---|
PSM-RB induction inhibits S-phase progression.
To study the
mechanism by which RB regulates S phase, Rat-1 cells harboring
inducible expression of active RB (PSM-RB) were generated (A2-4 cells).
PSM-RB migrates at a lower molecular weight than the endogenous rat RB,
enabling unambiguous detection of the induced PSM-RB protein
(26). As shown in Fig. 1A,
expression of PSM-RB was absent in the nontransduced parental line
(lanes 1 and 2), minimally detectable in the presence of Dox (lane 3), but readily apparent following removal of Dox from the medium for
16 h (lane 4). To examine the effect of PSM-RB expression on
cellular proliferation, growth curves were performed through counting
and trypan blue exclusion. In the presence of Dox, A2-4 cells doubled
approximately every 24 h, while in the absence of Dox,
proliferation ceased (Fig. 1B). After 6 days in culture, cells formed
tight colonies of proliferating cells in Dox medium, whereas single
cells exhibiting a large flattened morphology were observed in the
absence of Dox (not shown). Analysis of BrdU incorporation revealed
that induction of PSM-RB virtually halted DNA replication (Fig. 1C). To
specifically analyze the G1/S transition, A2-4 cells were
synchronized by culture in medium containing 0.1% FBS for 72 h.
Cells were then cultured for 24 h in fresh 0.1% FBS medium either
containing or lacking Dox to induce PSM-RB expression (Fig. 1D, hour
0). These quiescent cells were then stimulated with medium containing
10% FBS, harvested at 12, 18, 24, or 32 h post-serum stimulation,
and monitored for cell cycle entry by flow cytometry. With PSM-RB
expression inhibited (with Dox), cells entered the cell cycle within
18 h, as indicated by the accumulation of cells with a DNA content
greater than 2N (Fig. 1D, upper panel). In contrast, cells
expressing PSM-RB failed to exhibit cell cycle advancement out of
G1 over a 32-h period (Fig. 1D, lower panel). Thus, PSM-RB
expression retards the transition from G1 to S phase.
|
|
Active RB disrupts association of PCNA with chromatin.
We
hypothesized that RB must influence the activity of the replication
machinery to inhibit S-phase progression. During early G1,
the preRC is sequentially assembled at origins of replication and
contains ORC, cdc6, and MCM proteins (10, 11, 18, 25). Following activation of replication origins, PCNA is recruited to the
origin in S phase, where it functions as a homotrimeric clamp
facilitating the loading and processivity of DNA polymerase
. Both
PCNA and MCM2 are E2F-regulated genes, and as such would be candidates
for transcriptional regulation by RB.
|
PSM-RB does not inhibit RPA-chromatin association.
To further
refine the mechanism through which RB impacts the DNA replication
machinery, we analyzed the chromatin association of RPA. The RPA
heterotrimer (p32, p70, and p14) stabilizes single-stranded DNA as
origins unwind during initiation and is required at the replication
fork (61). Therefore, RPA tethering can be used as a
marker for early initiation events. Quiescent (as a control) and
S-phase-synchronized cells were subjected to in situ extraction and
immunostaining for RPA (p32 subunit). Consistent with its role in
S-phase, less than 5% of extracted quiescent cells retained detectable
RPA staining (Fig. 4A, top graph).
However, in S-phase-synchronized populations, RPA tethered to chromatin
was detectable in greater than 50% of the extracted cells, and this
association was not significantly inhibited by the expression of PSM-RB
(Fig. 4A, top graph, compare with and without Dox, and Fig. 4B). As a
control for these studies, we monitored PCNA staining (Fig. 4A, bottom graph). PCNA fails to significantly tether to chromatin in quiescent cells (Fig. 4A, bottom graph), and PCNA tethering was again diminished by the induction of PSM-RB (Fig. 4A, bottom graph, compare with and
without Dox). Results consistent with the immunostaining were also
observed by fractionation (not shown). Thus, PSM-RB does not perturb
the chromatin association of RPA while disrupting the tethering of
PCNA.
|
RB-mediated regulation of PCNA correlates with inhibition of
CDK2-cyclin A activity.
To determine if the effect of RB on PCNA
was direct, we examined the kinetics of RB induction and the
dissociation of PCNA from chromatin (Fig. 5A to
C). Cells were synchronized in S phase, and PSM-RB expression was induced by removal of Dox (in the presence of
APH). PSM-RB expression was first detected within 4 h of removal of Dox in APH-synchronized cultures (Fig. 5A). Analysis of PCNA tethering in these APH-synchronized cells by fractionation showed that
greater than 80% of tethered PCNA was dissociated from chromatin 16 h after removal of Dox (Fig. 5B). Similar results were observed by immunostaining analysis (Fig. 5C). Since PSM-RB expression significantly preceded the dissociation of PCNA from chromatin, this
suggested that RB does not act directly upon PCNA but that an
intermediate step is involved.
|
PCNA chromatin tethering is dependent on CDK2 activity and can be
dissociated from the presence of cyclin A.
Cyclin A is known to
bind PCNA as part of a ternary complex, suggesting that PCNA tethering
to chromatin may be dependent on cyclin A as a binding partner
(51), as opposed to the action of cyclin A as an activator
of CDK2. To differentiate between these two distinct activities of
cyclin A, we determined whether CDK2 activity is required for
PCNA-chromatin tethering. A pharmacological inhibitor of CDK2 activity,
olomucine, was used to inhibit CDK2 activity independent of PSM-RB
expression. As shown in Fig. 6A, 100 µM
olomucine significantly inhibited CDK2 activity (left panel, compare
duplicate experiments in lanes 3 and 4 versus 5 and 6). Cyclin A
expression was retained following 16 h of olomucine treatment in the
absence of PSM-RB expression, which contrasts with the ability of
PSM-RB to downregulate cyclin A over the same time period (right panel,
lanes 1 to 3). Analysis of PCNA activity in APH-synchronized cultures
showed that PCNA tethering was disrupted by olomucine (Fig. 6B, black
bars), while olomucine had no effect on total PCNA (Fig. 6B, gray
bars). Therefore, PCNA tethering in these S-phase cultures is dependent
on CDK2 activity and can be dissociated from the presence of cyclin A.
|
Restoration of CDK2-cyclin A facilitates PCNA tethering in presence
of active RB.
To assess the functional role of active CDK2-cyclin
A kinase in the disruption of PCNA-chromatin association by PSM-RB, we attempted to restore cyclin A protein in PSM-RB-expressing cells. Previous attempts to produce cyclin A in rat fibroblasts by
transfection were unsuccessful and coupled with cell death
(26). Therefore, we initially analyzed whether recombinant
human cyclin A-encoding adenovirus would be tolerated and induce cyclin
A expression in our cell cultures. APH-synchronized cells in the
presence or absence of PSM-RB expression were either mock infected or
infected with an adenovirus encoding both human cyclin A and GFP.
Sixteen hours postinfection, cyclin A protein levels were determined by
immunoblotting with antibodies which react preferentially against
rodent cyclin A (C19) (Fig. 7A,
top panel) or against human cyclin A (H432) (Fig. 7A,
bottom panel). Induction of PSM-RB reduced the expression of the
endogenous rat cyclin A protein in uninfected cells (Fig. 7A, compare
lanes 1 and 2). Expression of endogenous cyclin A was not significantly
rescued by infection with the adenovirus encoding human cyclin A (top
panel, lane 3), indicating that RB signaling to endogenous cyclin A was
intact following infection. However, the virus-encoded human cyclin A
was readily detected by immunoblotting (Fig. 7A, bottom panel, lane 3).
These cells showed no significant cell death after infection, and the
infections did not influence the level of PSM-RB in the cells (not
shown). Thus, cyclin A expression can be restored in the presence of
PSM-RB in this cell system. To confirm that infected cyclin A was
sufficient to restore CDK2 activity, CDK2 activity was monitored after
PSM-RB induction and cyclin A infection. As shown in Fig. 7B, cyclin A
infection restored CDK2 activity in the presence of PSM-RB (no Dox),
similar to levels observed in the absence of PSM-RB (with Dox) (compare
duplicate experiments in lanes 2 and 3 versus 4 and 5 versus 6 and 7).
|
Restoration of CDK2-cyclin A attenuates replication block elicited
by active RB.
Since PCNA tethering is required for efficient DNA
replication, we evaluated the ability of cells with restored
CDK2-cyclin A activity (via cyclin A infection) to progress through S
phase in the presence of PSM-RB expression (no Dox). Initially, cells were synchronized with APH, PSM-RB was induced by removal of Dox in the
presence of APH, and cells were immediately infected with either GFP or
GFP-cyclin A adenovirus. After 16 h, the cells were released from
APH and subjected to BrdU labeling for 4 h. Cells were fixed and
stained for BrdU incorporation. As shown in Fig. 8A, viral infection had
no influence on BrdU incorporation in the absence of PSM-RB expression,
as GFP or GFP-cyclin A-infected cells incorporated roughly equivalent
amounts of BrdU (60 to 70%). In the presence of PSM-RB, less than 10%
of GFP-infected cells incorporated BrdU following APH release (Fig. 8A,
GFP), similar to the inhibition observed in uninfected cells (Fig. 2C).
In cells infected with cyclin A, 27% of cells incorporated BrdU in the presence of PSM-RB expression (Fig. 8A, GFP plus cyclin A, no Dox).
Therefore, ectopic cyclin A expression significantly restored the
capacity for DNA replication in the presence of PSM-RB. Similar results
were observed with asynchronously proliferating cells (Fig. 8B). Less
than 5% of uninfected or GFP-infected cells incorporated BrdU upon
PSM-RB expression. Cyclin A expression led to 20% of cells
incorporating BrdU; however, this was significantly less than the
levels observed in cells which do not express PSM-RB (40 to 50%).
Although restoration of the CDK2-cyclin A-PCNA pathway was not
sufficient to completely bypass RB-mediated inhibition of DNA
replication, these results demonstrate that the ability of RB to
regulate PCNA activity is CDK2-cyclin A dependent and plays a critical
role in the regulation of DNA replication (Fig. 8C).
|
| |
DISCUSSION |
|---|
|
|
|---|
Recent studies have shown that RB inhibits cell cycle progression in S phase and that this function of RB is distinct from its role in G1. The S-phase inhibitory action of RB is invoked by specific types of stress, underscoring the importance of this function in controlling inappropriate cell cycle progression. However, the mechanism by which RB halts DNA replication has remained elusive. Here we report that RB regulates PCNA activity. Using cells harboring inducible expression of active PSM-RB, we showed that S-phase inhibition by RB coincided with the specific dissociation of PCNA from chromatin. This effect on PCNA was dependent on the downregulation of CDK2 kinase activity, as achieved (in the case of RB) through downregulation of cyclin A, and that RB-mediated PCNA regulation can be dissociated from the presence of cyclin A alone. Restoration of CDK2-cyclin A activity restored PCNA chromatin tethering even in the presence of activated RB. The critical nature of the RB-CDK2-PCNA pathway was indicated by the partial restoration of S-phase progression by ectopic cyclin A expression in the presence of PSM-RB. These studies delineate a signaling pathway from RB through CDK2 to the replication machinery in S phase (Fig. 8C).
RB is believed to mediate cell cycle inhibition by repressing the expression of numerous proteins whose promoters contain E2F binding sites (24). This mechanism of RB function is believed to act principally in G1, as the E2F partner DP-1 is inactive in S-phase cells (34, 35). However, we find that in S-phase cells RB does have the capacity to inhibit E2F-dependent transcription (not shown). Additionally, active RB expression in S-phase cells downregulates the cyclin A promoter and leads to attenuation of cyclin A RNA and protein levels. These results, coupled with studies on the RB-mediated DNA-damage response (31), indicate that the transcriptional repression function of RB contributes to S-phase inhibition.
The activity of CDK2-cyclin A complexes is important for DNA replication. CDK2-cyclin A has been shown to promote DNA replication in vitro (16), while ablation of CDK2 activity has been shown to inhibit DNA replication in vivo (45). Several DNA replication proteins are substrates for cyclin A-associated kinase activity; however, the role of their phosphorylation in the promotion of DNA replication is not clear (2, 12, 14, 17). For example, cdc6 is phosphorylated by CDK2-cyclin A and subsequently translocated to the cytoplasm and degraded (23, 48). However, the phosphorylation of cdc6 is apparently not required for DNA replication (47). CDK2-cyclin A complexes phosphorylate MCM proteins, but this phosphorylation inhibits their helicase activity, which would be contrary to a positive effect of cyclin A on DNA replication (22). RPA and the large subunit of DNA polymerase delta are substrates of CDK-cyclin complexes; however, phosphorylation has not been linked to changes in activity or DNA replication (61). For example, elimination of all CDK-cyclin sites in the RPA p32 subunit fails to influence RPA function (20), which is consistent with our finding that expression of PSM-RB and resultant inhibition of CDK2 activity does not inhibit RPA-chromatin association. During DNA replication, PCNA functions as a homotrimeric clamp, which facilitates the assembly and processivity of the DNA polymerase holoenzyme (61). In this active functional state, PCNA is tightly tethered to chromatin and resistant to extraction with low concentrations of Triton X-100. We find that in the absence of PSM-RB expression (and in the presence of CDK2-cyclin A), APH-synchronized cells exhibit PCNA tethering. This result is consistent with previous results that tethered PCNA is detected in APH-synchronized cells (3, 7). Following PSM-RB induction, PCNA association with chromatin was disrupted with a significant delay. This result argues against a direct influence of the RB protein on PCNA and for an intermediary step. We found that during this lag period, cyclin A protein levels were specifically attenuated, implying that RB leads to the dissociation of PCNA from chromatin via regulation of CDK2-cyclin A activity. The causal relationship between cyclin A and PCNA tethering was illustrated by restoring PCNA tethering through the ectopic expression of cyclin A in the APH-synchronized cells expressing PSM-RB. Interestingly, we failed to detect disruption of MCM2 or RPA tethering by PSM-RB. This finding indicates that PSM-RB does not target the establishment or maintenance of the preRC complex or early initiation events; rather, RB is targeting the recruitment of specific machinery involved in replication.
A variety of studies have shown that disruption of PCNA activity inhibits DNA replication. In Saccharomyces cerevisiae, mutation of PCNA stalls DNA replication (61). In mammalian cell extracts, disruption of PCNA function inhibits in vitro DNA replication (8, 49, 60). In the presence of PSM-RB, we find that although PCNA protein levels are not altered, the PCNA protein is no longer active, as determined by chromatin binding. Since efficient DNA replication does not occur in the absence of PCNA function, this clearly represents a mechanism through which RB inhibits DNA replication. Restoration of PCNA tethering through restored CDK2-cyclin A activity enabled a significant induction of DNA replication in the presence of active RB.
The RB-CDK2-cyclin A pathway is independent of the DNA damage-induced recruitment of PCNA, since DNA damage can actually rescue PCNA tethering in the presence of active RB. It is believed that PCNA is recruited to sites of DNA damage to facilitate repair processes. This role of PCNA in the DNA damage response has been previously dissociated from DNA replication. For example, in in vitro systems, it is possible to inhibit PCNA-dependent DNA replication without inhibiting nucleotide excision repair (55). Additionally, DNA damage promotes the chromatin association of PCNA in non-S-phase (quiescent) cells (59). How PCNA is recruited to damaged chromatin remains unclear and perhaps lesion specific. A number of PCNA-associated proteins are implicated in DNA damage response and repair (MSH2, MLH1, GADD45, and hRad9), suggesting that these factors could mediate chromatin association (15, 33, 50).
The mechanism through which CDK2-cyclin A acts to stimulate or maintain PCNA tethering is at present unknown. The requirement for cyclin A lies in its ability to activate CDK2 and not apparently the simple association of cyclin A with PCNA. Ectopic overproduction of cyclin E also promotes PCNA tethering in the presence of PSM-RB (not shown), further supporting the idea that CDK2 activity is the key determinant of PCNA activity. PCNA has a single conserved site (Thr-209) for CDK phosphorylation, and it has been shown that phosphorylated PCNA is specifically tethered to chromatin (51). However, the Thr-209 site has never been described as being phosphorylated or having functional consequence. While direct phosphorylation of PCNA is appealing, CDK2-cyclin A may stimulate phosphorylation of other components of the replication machinery, such as RFC, which are required to assemble PCNA complexes on chromatin (61). Our experiments demonstrate that in populations of APH-synchronized cells, where PCNA is largely tethered to chromatin, induction of PSM-RB disrupts this existing association. This finding suggests two possible mechanisms: first, that CDK2-cyclin A is required for maintaining PCNA on chromatin, and second, that PCNA is continuously dissociating and associating with chromatin and CDK2-cyclin A is required for PCNA loading. Interestingly, PCNA tethering is dependent on both cell cycle phase and the presence of cyclin A. In asynchronously proliferating cells, PCNA tethering was only observed in approximately 25% of cells, and after ectopic expression of cyclin A, there was no increase in PCNA tethering above this threshold, despite the observation that greater than 95% of cells were infected with cyclin A-producing adenovirus. Together, these results indicate that the inactivation of PCNA tethering by RB is an S-phase event which can be specifically restored through CDK2 activity.
Although ectopic cyclin A expression completely restored the tethering of PCNA to chromatin, it did not fully restore DNA replication in the presence of PSM-RB expression. It could be argued that high-level expression of cyclin A may have a deleterious effect on DNA replication; however, we failed to detect any influence of cyclin A on DNA replication in the absence of PSM-RB expression. Thus, PSM-RB likely has additional targets which are involved in DNA replication (Fig. 8C). In the absence of efficient RB-mediated transcriptional repression, RB fails to elicit cell cycle inhibition in both G1 and S phase (57, 65), suggesting that additional transcriptional targets of RB may facilitate the inhibition of S-phase progression. Clearly the requirement for these targets is not strictly essential for replication, since the ectopic expression of cyclin A does facilitate DNA replication in approximately half of the PSM-RB arrested cells. Since RB represses the expression of numerous proteins involved in nucleotide biosynthesis (13, 44), an intriguing possibility would be that the levels of these enzymes and/or pools of deoxyribonucleotides might dictate whether replication is capable of proceeding in the presence of ectopic cyclin A expression.
In summary, we demonstrate that active RB inhibits CDK2-cyclin A activity in S phase, resulting in the loss of PCNA-chromatin association. These data reveal a new pathway of RB function that contributes to its efficacy as an inhibitor of cellular proliferation.
| |
ACKNOWLEDGMENTS |
|---|
We thank Shelley Barton, Kenji Fukasawa, Jean Wang, and Peter Stambrook for thought provoking discussion and critical reading of the manuscript. We are grateful to Sofie Salama and Ed Harlow for the provision of Rat-16 cells. RPA antibodies were kindly provided by Thomas Melendy and Marc Wold. George Babcock and Jim Cornelius provided exquisite flow cytometric analysis. Special thanks to Gustavo Leone, who provided the recombinant adenoviruses.
This work was supported by grant CA82525 to E.S.K. from the NIH/NCI. E.S.K. is a Kimmel Scholar.
The first two authors contributed equally.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Dept. of Cell Biology, Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0521. Phone: (513) 558-8885. Fax: (513) 558-4454. E-mail: erik.knudsen{at}uc.edu.
Present address: University of Texas Health Center at Tyler, Tyler,
TX 35708.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bartek, J., J. Bartkova, and J. Lukas. 1997. The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 237:1-6[CrossRef][Medline]. |
| 2. |
Bashir, T.,
R. Horlein,
J. Rommelaere, and K. Willwand.
2000.
Cyclin A activates the DNA polymerase delta-dependent elongation machinery in vitro: a parvovirus DNA replication model.
Proc. Natl. Acad. Sci. USA
97:5522-5527 |
| 3. | Bravo, R. 1986. Synthesis of the nuclear protein cyclin (PCNA) and its relationship with DNA replication. Exp. Cell Res. 163:287-293[CrossRef][Medline]. |
| 4. | Brehm, A., E. A. Miska, D. J. McCance, J. L. Reid, A. J. Bannister, and T. Kouzarides. 1998. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597-601[CrossRef][Medline]. |
| 5. | Bremner, R., B. L. Cohen, M. Sopta, P. A. Hamel, C. J. Ingles, B. L. Gallie, and R. A. Phillips. 1995. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol. Cell. Biol. 15:3256-3265[Abstract]. |
| 6. | Brylawski, B. P., S. M. Cohen, J. L. Longmire, N. A. Doggett, M. Cordeiro-Stone, and D. G. Kaufman. 2000. Construction of a cosmid library of DNA replicated early in the S phase of normal human fibroblasts. J. Cell. Biochem. 78:509-517[CrossRef][Medline]. |
| 7. | Bunch, R. T., and A. Eastman. 1997. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ. 8:779-788[Abstract]. |
| 8. |
Chen, J.,
R. Peters,
P. Saha,
P. Lee,
A. Theodoras,
M. Pagano,
G. Wagner, and A. Dutta.
1996.
A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo.
Nucleic Acids Res.
24:1727-1733 |
| 9. | Chew, Y. P., M. Ellis, S. Wilkie, and S. Mittnacht. 1998. pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F. Oncogene 17:2177-2186[CrossRef][Medline]. |
| 10. |
Dimitrova, D. S.,
I. T. Todorov,
T. Melendy, and D. M. Gilbert.
1999.
Mcm2, but not RPA, is a component of the mammalian early G1-phase prereplication complex.
J. Cell. Biol.
146:709-722 |
| 11. | Dimitrova, D. S., and D. M. Gilbert. 2000. Temporally coordientated assembly and disassembly of replication factories in the absence of DNA synthesis. Nat. Cell Biol. 2:686-694[CrossRef][Medline]. |
| 12. | Donovan, S., and J. F. Diffley. 1996. Replication origins in eukaroytes. Curr. Opin. Genet. Dev. 6:203-207[CrossRef][Medline]. |
| 13. |
Dyson, N.
1998.
The regulation of E2F by pRB-family proteins.
Genes Dev.
12:2245-2262 |
| 14. | Findeisen, M., M. El-Denary, T. Kapitza, R. Graf, and U. Strausfeld. 1999. Cyclin A-dependent kinase activity affects chromatin binding of ORC, Cdc6, and MCM in egg extracts of Xenopus laevis. Eur. J. Biochem. 264:415-426[Medline]. |
| 15. | Flores-Rozas, H., D. Clark, and R. D. Kolodner. 2000. Proliferating cell nuclear antigen and Msh2p-Msh6p interact to form an active mispair recognition complex. Nat. Genet. 26:375-378[CrossRef][Medline]. |
| 16. |
Fotedar, A.,
D. Cannella,
P. Fitzgerald,
T. Rousselle,
S. Gupta,
M. Doree, and R. Fotedar.
1996.
Role for cyclin A-dependent kinase in DNA replication in human S phase cell extracts.
J. Biol. Chem.
271:31627-31637 |
| 17. | Fotedar, R., and A. Fotedar. 1995. Cell cycle control of DNA replication. Prog. Cell Cycle Res. 1:73-89[Medline]. |
| 18. | Fujita, M. 1999. Cell cycle regulation of DNA replication initiation proteins in mammalian cells. Front. Biosci. 4:D816-D823[Medline]. |
| 19. |
Fujita, M.,
T. Kiyono,
Y. Hayashi, and M. Ishibashi.
1996.
hCDC47, a human member of the MCM family: dissociation of the nucleus-bound form during S phase.
J. Biol. Chem.
271:4349-4354 |
| 20. |
Henricksen, L. A., and M. S. Wold.
1994.
Replication protein A mutants lacking phosphorylation sites for p34cdc2 kinase support DNA replication J.
Biol. Chem.
269:24203-24208 |
| 21. | Hinds, P. W., S. Mittnacht, V. Dulic, A. Arnold, S. I. Reed, and R. A. Weinberg. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006[CrossRef][Medline]. |
| 22. |
Ishimi, Y.,
Y. Komamura-Kohno,
Z. You,
A. Omori, and M. Kitagawa.
2000.
Inhibition of Mcm4,6,7 helicase activity by phosphorylation with cyclin A/Cdk2.
J. Biol. Chem.
275:16235-16241 |
| 23. |
Jiang, W.,
N. J. Wells, and T. Hunter.
1999.
Multistep regulation of DNA replication by Cdk phosphorylation of HsCdc6.
Proc. Natl. Acad. Sci. USA
96:6193-6198 |
| 24. | Kaelin, W. G., Jr. 1997. Recent insights into the functions of the retinoblastoma susceptibility gene product. Cancer Investig. 15:243-254[Medline]. |
| 25. | Kearsey, S. E., D. Maiorano, E. C. Holmes, and I. T. Todorov. 1996. The role of MCM proteins in the cell cycle control of genome duplication. Bioessays 18:183-190[CrossRef][Medline]. |
| 26. |
Knudsen, E. S.,
C. Buckmaster,
T. T. Chen,
J. R. Feramisco, and J. Y. Wang.
1998.
Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression.
Genes Dev.
12:2278-2292 |
| 27. |
Knudsen, E. S., and J. Y. Wang.
1996.
Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites.
J. Biol. Chem.
271:8313-8320 |
| 28. | Knudsen, E. S., and J. Y. Wang. 1997. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol. Cell. Biol. 17:5771-5783[Abstract]. |
| 29. | Knudsen, K. E., E. Weber, K. C. Arden, W. K. Cavenee, J. R. Feramisco, and E. S. Knudsen. 1999. RB inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene 20:345-349. |
| 30. |
Knudsen, K. E.,
K. C. Arden, and W. K. Cavenee.
1998.
Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.
J. Biol. Chem.
273:20213-20222 |
| 31. |
Knudsen, K. E.,
D. Booth,
S. Naderi,
Z. Sever-Chroneos,
A. F. Fribourg,
I. Hunton,
J. R. Feramisco,
J. Y. J. Wang, and E. S. Knudsen.
2000.
RB-dependent S-phase response to DNA-damage.
Mol. Cell. Biol.
20:7751-7763 |
| 32. |
Knudsen, K. E.,
A. F. Fribourg,
M. W. Strobeck,
J. M. Blanchard, and E. S. Knudsen.
1999.
Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest.
J. Biol. Chem.
274:27632-27641 |
| 33. | Komatsu, K., W. Wharton, H. Hang, C. Wu, S. Singh, H. B. Lieberman, W. J. Pledger, and H. G. Wang. 2000. PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition. Oncogene 19:5291-5297[CrossRef][Medline]. |
| 34. | Krek, W., M. E. Ewen, S. Shirodkar, Z. Arany, W. G. Kaelin, Jr., and D. M. Livingston. 1994. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 78:161-172[CrossRef][Medline]. |
| 35. | Krek, W., G. Xu, and D. M. Livingston. 1995. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 83:1149-1158[CrossRef][Medline]. |
| 36. |
Levenson, V., and J. L. Hamlin.
1993.
A general protocol for evaluating the specific effects of DNA replication inhibitors.
Nucleic Acids Res.
21:3997-4004 |
| 37. | Lukas, C., C. S. Sorensen, E. Kramer, E. Santoni-Rugiu, C. Lindeneg, J. M. Peters, J. Bartek, and J. Lukas. 1999. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 401:815-818[CrossRef][Medline]. |
| 38. | Lukas, J., J. Bartkova, M. Rohde, M. Strauss, and J. Bartek. 1995. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15:2600-2611[Abstract]. |
| 39. |
Lukas, J.,
T. Herzinger,
K. Hansen,
M. C. Moroni,
D. Resnitzky,
K. Helin,
S. I. Reed, and J. Bartek.
1997.
Cyclin E-induced S phase without activation of the pRb/E2F pathway.
Genes Dev.
11:1479-1492 |
| 40. | Lukas, J., D. Parry, L. Aagaard, D. J. Mann, J. Bartkova, M. Strauss, G. Peters, and J. Bartek. 1995. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503-506[CrossRef][Medline]. |
| 41. | Lukas, J., C. S. Sorensen, C. Lukas, E. Santoni-Rugiu, and J. Bartek. 1999. p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis. Oncogene 18:3930-3935[CrossRef][Medline]. |
| 42. | Magnaghi-Jaulin, L., R. Groisman, I. Naguibneva, P. Robin, S. Lorain, J. P. Le Villain, F. Troalen, D. Trouche, and A. Harel-Bellan. 1998. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391:601-605[CrossRef][Medline]. |
| 43. | Mittnacht, S. 1998. Control of pRB phosphorylation. Curr. Opin. Genet. Dev. 8:21-27[CrossRef][Medline]. |